You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

DEFB1 protein, human

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Esophageal Cancer, Pancreas Cancer, Ovarian Cancer Trial in Edegem (IL15-transpresenting WT1-targeted Dendritic Cell Vaccine)

Not yet recruiting
  • Esophageal Cancer
  • +3 more
  • IL15-transpresenting WT1-targeted Dendritic Cell Vaccine
  • Edegem, Belgium
    Antwerp University Hospital
Jul 19, 2023

Chronic Lung Disease of Prematurity, Respiratory Distress Syndrome in Premature Infant, Bronchopulmonary Dysplasia Trial

Not yet recruiting
  • Chronic Lung Disease of Prematurity
  • +2 more
  • Recombinant fragment of human surfactant protein D (rfhSP-D)
  • (no location specified)
Jun 6, 2023

Advanced Solid Tumors Trial (VVD-130037)

Not yet recruiting
  • Advanced Solid Tumors
  • (no location specified)
Jul 12, 2023

Health Volunteer Trial in Beijing (Recombinant human CTLA-4-FC fusion protein for injection 1mg/kg, Recombinant human CTLA-4-FC

Recruiting
  • Health Volunteer
  • Recombinant human CTLA-4-FC fusion protein for injection 1mg/kg
  • +9 more
  • Beijing, China
    Peking University People's Hospital
Feb 15, 2022

Type 2 Diabetes, HbA1c, Protein Intake Trial in Saratoga Springs (PP)

Recruiting
  • Type 2 Diabetes
  • +2 more
  • PP
  • Saratoga Springs, New York
    Human Nutrition and Metabolism Laboratory
Apr 25, 2022

Advanced Solid Tumors Trial in Australia (HLX20)

Completed
  • Advanced Solid Tumors
  • Darlinghurst, New South Wales, Australia
  • +5 more
Jun 1, 2022

Hematologic Malignancy Trial in Tianjin (IMM01)

Terminated
  • Hematologic Malignancy
  • Tianjin, Tianjin, China
    Chinese Academy of Medical Sciences and Peking Union Medical Col
May 5, 2023

Locally Advanced Basal Cell Carcinoma Trial in Philadelphia (biological, procedure, other)

Not yet recruiting
  • Locally Advanced Basal Cell Carcinoma
  • Cemiplimab
  • +3 more
  • Philadelphia, Pennsylvania
    Thomas Jefferson University Hospital
Jun 28, 2023

Adenocarcinoma, Gastric, Tumor, Breast Trial in Taipei (DS-8201a)

Completed
Has Results
  • Adenocarcinoma, Gastric
  • Neoplasm, Breast
  • Taipei, Taiwan
  • +1 more
Nov 2, 2022

Advanced Malignant Solid Tumor Trial in France, Netherlands (MP0317, a tri-specific fibroblast activation protein (FAP) x CD40

Recruiting
  • Advanced Malignant Solid Tumor
  • MP0317, a tri-specific fibroblast activation protein (FAP) x CD40 DARPin® drug candidate
  • Lyon, Cedex 08, France
  • +3 more
Nov 4, 2022

Sarcopenia Trial in Coleraine / Limerick (Intervention, Control)

Not yet recruiting
  • Sarcopenia
  • Intervention
  • Control
  • Coleraine / Limerick, Co.Londonderry / Ireland, United Kingdom
    Human Intervention Studies Unit, Ulster University / Physical Ed
Apr 27, 2022

Chronic Lymphocytic Leukemia, Richter Syndrome, Small Lymphocytic Lymphoma Trial in Rochester (Acalabrutinib, Durvalumab,

Recruiting
  • Chronic Lymphocytic Leukemia
  • +2 more
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Jan 4, 2023

Congenital Protein C Deficiency Trial in Kashihara, Chiba, Saitama (TAK-662)

Active, not recruiting
  • Congenital Protein C Deficiency
  • Kashihara, Nara, Japan
  • +3 more
Apr 7, 2022

Retinitis Pigmentosa Trial in Stockholm (CPK850)

Recruiting
  • Retinitis Pigmentosa
  • CPK850
  • Stockholm, Sweden
    Novartis Investigative Site
May 16, 2022

COVID-19 Trial in Herston (UQSC2 Vaccine, NVX-CoV2373 vaccine)

Not yet recruiting
  • COVID-19
  • UQSC2 Vaccine
  • NVX-CoV2373 vaccine
  • Herston, Queensland, Australia
    Q-Pharm Pty Ltd (Nucleus Network Brisbane)
Mar 8, 2023

Lyme Disease Trial in Lincoln (2217LS, 0.9% Sodium Chloride (NaCl))

Completed
  • Lyme Disease
  • 2217LS
  • 0.9% Sodium Chloride (NaCl)
  • Lincoln, Nebraska
    Celerion Inc.
Sep 15, 2022

Tumor Malignant, Tumor, Experimental, Solid Tumor, Adult Trial in Taipei (JS014, Interleukin 21 and humanized anti-human serum

Active, not recruiting
  • Neoplasm Malignant
  • +3 more
  • JS014, Interleukin 21 and humanized anti-human serum albumin VHH antibody
  • Pembrolizumab - anti-PD-1 antibody
  • Taipei, Taiwan
    Wanfang Hospital -Taipei Medical University
Mar 16, 2022

ctDNA Methylation for Epithelial Ovarian Cancer

Recruiting
  • Epithelial Ovarian Cancer
  • +7 more
  • CDO1 and HOXA9 methylation assay
  • Beijing, Beijing, China
    Lei Li
Mar 24, 2023

ctDNA Methylation for Detecting Ovarian Cancer

Recruiting
  • Epithelial Ovarian Cancer
  • +8 more
  • Methylation assay
  • Beijing, Beijing, China
    Lei Li
Mar 24, 2023

HIV, Systemic Lupus Erythematosus Trial in Durham (AIDSVAX® B/E)

Completed
Has Results
  • HIV Infections
  • Systemic Lupus Erythematosus
  • AIDSVAX® B/E
  • Durham, North Carolina
    Duke Human Vaccine Institute CRS
Jan 31, 2022

Dystrophic Epidermolysis Bullosa Trial in Stanford (Topical beremagene geperpavec)

Completed
Has Results
  • Dystrophic Epidermolysis Bullosa
  • Topical beremagene geperpavec
  • Placebo gel
  • Stanford, California
    Stanford University
Jan 30, 2023

Locally Advanced Intrahepatic Cholangiocarcinoma, Oligometastatic Intrahepatic Cholangiocarcinoma, Stage III Intrahepatic

Not yet recruiting
  • Locally Advanced Intrahepatic Cholangiocarcinoma
  • +4 more
  • Angiography
  • +8 more
  • Jacksonville, Florida
    Mayo Clinic in Florida
Sep 22, 2023

Borderline Resectable Pancreatic Adenocarcinoma, Resectable Pancreatic Adenocarcinoma, Stage IA Pancreatic Cancer AJCC v8 Trial

Recruiting
  • Borderline Resectable Pancreatic Adenocarcinoma
  • +5 more
  • Durvalumab
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Oct 12, 2022

Biochemically Recurrent Prostate Carcinoma, Prostate Adenocarcinoma Trial in Seattle (biological, drug, other)

Recruiting
  • Biochemically Recurrent Prostate Carcinoma
  • Prostate Adenocarcinoma
  • Durvalumab
  • +3 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jan 26, 2023

Recurrent Bladder Carcinoma, Bladder Cancer Stage 0, Bladder Cancer Stage I Trial in Los Angeles (Pharmacokinetic Study,

Not yet recruiting
  • Recurrent Bladder Carcinoma
  • +2 more
  • Pharmacokinetic Study
  • Recombinant EphB4-HSA Fusion Protein
  • Los Angeles, California
    USC / Norris Comprehensive Cancer Center
Jan 31, 2023